Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Zisowsky

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2025
Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular EventsAshraf Yassen, Friederike Kanefendt, Jochen Zisowsky, et al.
Clinical Pharmacokinetics|December 23, 2015
Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose SelectionAndreas Krause, Jochen Zisowsky, Daniel S Strasser, et al.
Journal of Clinical Pharmacology|February 7, 2015
A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjectsMartine Géhin, Daniel S Strasser, Jochen Zisowsky, et al.
The American Journal of Pathology|November 30, 2005
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2Giuliano Ciarimboli, Thomas Ludwig, Detlef Lang, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2025
Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular EventsAshraf Yassen, Friederike Kanefendt, Jochen Zisowsky, et al.
Clinical Pharmacokinetics|December 23, 2015
Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose SelectionAndreas Krause, Jochen Zisowsky, Daniel S Strasser, et al.
Journal of Clinical Pharmacology|February 7, 2015
A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjectsMartine Géhin, Daniel S Strasser, Jochen Zisowsky, et al.
The American Journal of Pathology|November 30, 2005
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2Giuliano Ciarimboli, Thomas Ludwig, Detlef Lang, et al.
Pageof 2